Abstracts Archive - Page 2464 of 2605 - ACR Meeting Abstracts

Abstract Number: 2063 • 2012 ACR/ARHP Annual Meeting
Detection of Inflammatory Arthritis and Musculoskeletal Conditions in a First Nations Community: Results of an Onsite Screening Program
Cheryl Barnabe¹, Carrissa Low Horn², Margaret Kargard², Stephen Mintsioulis², Sharon Leclercq³, Dianne P. Mosher⁴, Hani S. El-Gabalawy⁵, Tyler White² and Marvin J. Fritzler⁶, ¹Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ²Siksika Health Services, Siksika, AB, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Med, University of Calgary, Calgary, AB, Canada, ⁵Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: RA and SLE are more severe and at least twice as prevalent in the First Nations population of Canada compared to the Caucasian population.…
Abstract Number: 2064 • 2012 ACR/ARHP Annual Meeting
Regular Measure of Disease Activity During the Routine Care of Rheumatoid Arthritis Patients Involves Some Extra Work but Positive Results
Lissiane K. N. Guedes¹, Ana Cristina Medeiros Ribeiro², Karina Rossi Bonfiglioli³, Diogo Domiciano¹, Carolina Reither Vizioli¹, Gilmara Franco da Cunha¹, Andressa Silva Abreu¹, Filipi M. Mello¹, Ana Luiza de Aguiar Foelkel⁴, Celio R. Gonçalves¹ and Ieda Laurindo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: According to treat to target recommendations the use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical…
Abstract Number: 2065 • 2012 ACR/ARHP Annual Meeting
Uptake of the American College of Rheumatology’s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data
Salahuddin Kazi¹, Itara Barnes², Jinoos Yazdany³ and Rachel Myslinski⁴, ¹Internal Medicine/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ²Quality, Registries, and Health Informatics, American College of Rheumatology, Atlanta, GA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Practice, Advocacy, & Quality, American College of Rheumatology, Atlanta, GA
Background: The RCR was launched by the ACR to provide members with an infrastructure for quality reporting related to rheumatoid arthritis, gout, osteoarthritis, osteoporosis, and…
Abstract Number: 2066 • 2012 ACR/ARHP Annual Meeting
Improving Outpatient Follow-up for Osteoporosis Management After a Hip Fracture
Anika Alarakhia and Robert Quinet, Rheumatology, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Patients hospitalized for hip fractures are routinely scheduled for a Rheumatology follow-up appointment to assess their risk of future fractures and need for treatment.…
Abstract Number: 2067 • 2012 ACR/ARHP Annual Meeting
Access to Technology and Interest in Mobile “app” for Disease Management Among Patients with Systemic Lupus Erythematosus Seeking Care At a Large Referral Center
Wendy Marder¹, Holly Witteman², Margaret Hyzy³, Martha Ganser¹, Emily C. Somers⁴ and Lawrence An⁵, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²The Center for Bioethics and Social Sciences in Medicine, University of Michigan Medical School, Ann Arbor, MI, ³Internal Medicine, Universitiy of Michigan, Ann Arbor, MI, ⁴IntMed, Environmental Health, and OB/GYN, University of Michigan, Ann Arbor, MI, ⁵Center for Health Communications Research, Universitiy of Michigan, Ann Arbor, MI
Background/Purpose: Some of the challenges facing patients with chronic diseases such as systemic lupus erythematosus (SLE) include identifying triggers for disease “flares” and accurately recalling…
Abstract Number: 2068 • 2012 ACR/ARHP Annual Meeting
Is There a Difference in Rheumatology Patient Reported Outcomes When Measured At Home Versus the Clinic Setting?
C.J. Inman¹, Frederick Wolfe² and Kaleb Michaud³, ¹Pediatric Administration, University of Utah, Salt Lake City, UT, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Registries have become a common tool for collecting patient-centered outcome measures. Clinical effectiveness research may be improved if data from multiple registries could be…
Abstract Number: 2069 • 2012 ACR/ARHP Annual Meeting
Proteinase Activated Receptor-4 Stimulation Promotes Leukocyte Adhesion in the Rat Knee Joint
Jason J. McDougall, Departments of Pharmacology and Anaesthesia, Dalhousie University, Halifax, NS, Canada
Background/Purpose: Proteinase activated receptors (PARs) are a family of G protein-coupled receptors that signal by enzymatic cleavage of the receptor in a specific extracellular domain.…
Abstract Number: 2070 • 2012 ACR/ARHP Annual Meeting
Myeloid-Derived Suppressor Cells Accumulated in Spleens of Mice with Collagen-Induced Arthritis and Inhibited Immune Response of CD4⁺ T Cells
Wataru Fujii¹, Eishi Ashihara², Hideyo Hirai³, Hidetake Nagahara¹, Kazuki Fujioka¹, Ken Murakami¹, Kaoru Nakamura¹, Takahiro Seno¹, Aihiro Yamamoto¹, Hidetaka Ishino¹, Masataka Kohno¹, Taira Maekawa³ and Yutaka Kawahito¹, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan, ³Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan
Background/Purpose: Myeloid-derived suppressor cells (MDSCs), firstly reported in patients with cancer, have a myeloid origin and an ability to suppress T cell responses. MDSCs are…
Abstract Number: 2071 • 2012 ACR/ARHP Annual Meeting
The Potent, Highly Selective and Orally Bioavailable Spleen Tyrosine Kinase Inhibitor GSK143 Demonstrates Efficacy in B Cell Receptor and Fc Receptor Signalling in Models of Inflammatory and Autoimmune Disease
Marion C. Dickson¹, Nicholas Smithers², Huw Lewis¹, Cesar Ramirez-Molina¹, Scott McCleary¹, Mike Barker¹ and John Liddle¹, ¹Immuno Inflammation, GSK, Stevenage, United Kingdom, ²Immuno Inflammation, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Spleen tyrosine kinase (Syk), a 72 KDa cytosolic non-receptor tyrosine kinase is a key mediator of B cell receptor (BCR) and Fc receptor (FcR)…
Abstract Number: 2072 • 2012 ACR/ARHP Annual Meeting
Bone Formation and Resorption Are Both Increased in Autoimmune Arthritis
Kresten K. Keller¹, Jesper Skovhus Thomsen², Kristian Stengaard-Pedersen¹, Frederik Dagnæs-Hansen³, Jens R. Nyengaard⁴ and Ellen-Margrethe Hauge¹, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Institute of Anatomy, Aarhus University, ³Institute of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark, ⁴Stereology and Electron Microscopy Laboratory, Centre for Stochastic Geometry and Advanced Bioimaging. Aarhus University hospital, Aarhus, Denmark
Background/Purpose: Bone destruction in the joints of patients with rheumatoid arthritis (RA) is the result of a combination of osteoclastic bone resorption and osteoblastic bone…
Abstract Number: 2073 • 2012 ACR/ARHP Annual Meeting
Green Tea Epigallocatechin-3-Gallate Ameliorates Murine Arthritis by Inducing IDO Producing Dendritic Cells Via Nrf2 Antioxidant Pathway
Soyoun Min¹, Mei Yan¹, Kamala Vanarsa², Anna Bashmakov¹ and Chandra Mohan¹, ¹Internal Medicine/Division of Rheumatology, University of Texas Southwestern Medical Center, Dallas, TX, ²Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: To examine the immunomodulatory effects and mechanisms of Green Tea (−)-epigallocatechin-3-gallate (EGCG) on experimental arthritis in mice, we investigated whether EGCG can afford therapeutic…
Abstract Number: 2074 • 2012 ACR/ARHP Annual Meeting
Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Tomomi Date¹, Yukihiko Aikawa¹, Tetsuya Yamamoto¹, Hirokazu Narita¹, Shuichi Hirono² and Shunichi Shiozawa³, ¹Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, ²Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, ³Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Activator protein-1 (AP-1) is an important transcription factor for cytokine production and joint destruction in rheumatoid arthritis (RA), and a potential target for the…
Abstract Number: 2075 • 2012 ACR/ARHP Annual Meeting
CCR6⁺Foxp3⁺ Regulatory T Cells Regulate the Development of Collagen Induced Arthritis in T Cell Specific RORγt Transgenic Mice
Yuya Kondo¹, Masahiro Tahara¹, Mana Iizuka¹, Hiroto Tsuboi¹, Satoru Takahashi², Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan
Background/Purpose: Recent studies reported that IL-17 producing Th-17 cells appear to play an important role in the generation of several autoimmune arthritis models. We previously…
Abstract Number: 2076 • 2012 ACR/ARHP Annual Meeting
Efficacy of the Potent PI3K-δ,γ Inhibitor IPI-145 in Rat Adjuvant Arthritis
David L. Boyle¹, Katharyn Topoleweski¹ and Gary S. Firestein², ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Phosphoinositide 3-kinase (PI3K) is a family of intracellular signaling transducers and could be targeted to treat inflammatory diseases like rheumatoid arthritis (RA). However, blockade…
Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Miho Suzuki¹, Hiroto Yoshida², Misato Hashizume¹, Masashi Shiina², Keisuke Tanaka¹ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].